Coinbase
COIN
Tesla
TSLA
Strategy
MSTR
NVIDIA
NVDA
Salesforce
CRM
US Stock MarketDetailed Quotes
ATRA Atara Biotherapeutics
- 6.105
- -0.055-0.89%
Trading Mar 11 11:48 ET
35.77MMarket Cap-0.54P/E (TTM)
6.445High5.960Low36.35KVolume6.240Open6.160Pre Close222.48KTurnover0.86%Turnover RatioLossP/E (Static)5.86MShares20.81352wk High-0.37P/B25.69MFloat Cap5.40052wk Low--Dividend TTM4.21MShs Float1638.998Historical High--Div YieldTTM7.87%Amplitude4.965Historical Low6.120Avg Price1Lot Size
Atara Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 64.39%-68.72M | 51.45%-24.47M | 92.23%-3.99M | 79.84%-10.65M | 22.94%-29.61M | 28.64%-192.98M | 11.38%-50.41M | 21.08%-51.35M | 17.46%-52.8M | 54.54%-38.43M |
| Net income from continuing operations | 69.07%-85.4M | 79.00%-12.69M | 68.61%-21.91M | 73.21%-19.05M | 57.53%-31.75M | -20.95%-276.13M | 18.94%-60.45M | 17.00%-69.8M | -485.08%-71.11M | 15.13%-74.77M |
| Depreciation and amortization | 4.60%5.05M | -8.71%1.1M | 1.74%1.23M | 10.74%1.33M | 14.58%1.39M | -14.58%4.83M | -3.98%1.21M | -11.69%1.21M | -16.48%1.2M | -23.70%1.21M |
| Other non cash items | -5.76%15.83M | -4.56%3.89M | -13.31%3.76M | -2.11%4.13M | -2.76%4.05M | 85.40%16.8M | 41.12%4.08M | 56.60%4.34M | 52.51%4.22M | 556.62%4.16M |
| Change In working capital | -301.81%-30.96M | -207.89%-22.41M | 232.76%6.56M | -409.23%-3.38M | -160.01%-11.73M | 124.96%15.34M | -440.84%-7.28M | 178.93%1.97M | 102.15%1.09M | 245.02%19.55M |
| -Change in receivables | 433.72%32.63M | 99.57%-147K | 215.99%1.09M | 30,474.55%33.41M | -104.33%-1.73M | 115.58%6.11M | 15.08%-33.95M | -11.34%344K | -454.84%-110K | 12,423.27%39.82M |
| -Change in inventory | 45.39%-4.43M | 94.86%-160K | 275.51%4.77M | -5.71%-2.67M | -69.90%-6.38M | -411.98%-8.12M | -96.41%-3.12M | --1.27M | ---2.52M | ---3.75M |
| -Change in payables and accrued expense | -5.34%-13.62M | 135.31%2.95M | -80.81%1.45M | -3,454.64%-9.95M | 31.91%-8.07M | -150.59%-12.93M | -406.60%-8.36M | 184.97%7.57M | -112.31%-280K | 7.49%-11.86M |
| -Change in other current assets | -191.79%-1.21M | 323.50%2.18M | -602.16%-3.73M | -30.15%1.96M | 40.95%-1.62M | -16.18%1.32M | -90.82%515K | 118.02%742K | 11,096.00%2.8M | -5,472.55%-2.74M |
| -Change in other current liabilities | -1,579.51%-24.02M | -170.86%-5.51M | 4.87%-5.69M | -728.12%-10.41M | 50.56%-2.42M | 74.41%-1.43M | 267.33%7.77M | -2,632.20%-5.98M | 2,816.39%1.66M | -337.33%-4.89M |
| -Change in other working capital | -166.80%-20.3M | -172.76%-21.72M | 538.96%8.67M | -3,386.47%-15.72M | 185.94%8.48M | 365.04%30.4M | -25.36%29.86M | ---1.97M | 99.11%-451K | 664.76%2.97M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 64.39%-68.72M | 51.45%-24.47M | 92.23%-3.99M | 79.84%-10.65M | 22.94%-29.61M | 28.64%-192.98M | 11.38%-50.41M | 21.08%-51.35M | 17.46%-52.8M | 54.54%-38.43M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -93.04%8.62M | -66.05%3.38M | -123.66%-16.67M | -85.46%7.2M | 345.00%14.72M | -38.97%123.87M | -80.58%9.94M | 18.01%70.45M | 55.48%49.48M | -109.98%-6.01M |
| Net PPE purchase and sale | 79.47%-246K | -104.55%-90K | --0 | 94.19%-29K | 68.17%-127K | -101.32%-1.2M | -18.92%-44K | -93.94%-256K | -100.53%-499K | 84.68%-399K |
| Net investment purchase and sale | -92.91%8.87M | -65.30%3.47M | -123.57%-16.67M | -85.54%7.23M | 364.69%14.84M | 11.28%125.06M | -80.51%9.99M | 18.18%70.7M | 181.24%49.98M | -108.93%-5.61M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -93.04%8.62M | -66.05%3.38M | -123.66%-16.67M | -85.46%7.2M | 345.00%14.72M | -38.97%123.87M | -80.58%9.94M | 18.01%70.45M | 55.48%49.48M | -109.98%-6.01M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,849.35%59.28M | -121.69%-328K | 17,308.17%35.79M | -168.79%-324K | 10,172.77%24.14M | -96.21%2.01M | -95.32%1.51M | 2.80%-208K | -59.29%471K | -98.82%235K |
| Net issuance payments of debt | 5.81%-892K | -9.30%-235K | 5.29%-197K | -9.91%-233K | 27.24%-227K | -82.82%-947K | -76.23%-215K | -0.97%-208K | -68.25%-212K | -387.50%-312K |
| Net common stock issuance | 2,706.69%59.95M | -113.58%-210K | --50.81M | -29,952.00%-15.03M | 3,708.44%24.37M | -90.24%2.14M | 12.44%1.55M | --0 | -117.39%-50K | -96.88%640K |
| Proceeds from stock option exercised by employees | -75.22%230K | -35.36%117K | --0 | -84.87%113K | --0 | -51.69%928K | -61.41%181K | --0 | -42.93%747K | --0 |
| Net other financing activities | 93.46%-7K | --0 | --0 | 92.86%-1K | 93.55%-6K | -100.36%-107K | --0 | --0 | -366.67%-14K | 87.08%-93K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,849.35%59.28M | -121.69%-328K | 17,308.17%35.79M | -168.79%-324K | 10,172.77%24.14M | -96.21%2.01M | -95.32%1.51M | 2.80%-208K | -59.29%471K | -98.82%235K |
| Net cash flow | ||||||||||
| Beginning cash position | -72.08%25.99M | -28.24%46.6M | -31.67%31.46M | -27.93%35.23M | -72.08%25.99M | -13.39%93.09M | -2.29%64.94M | -36.08%46.04M | -52.54%48.89M | -13.39%93.09M |
| Current changes in cash | 98.79%-811K | 45.00%-21.42M | -19.87%15.14M | -32.71%-3.77M | 120.92%9.25M | -366.30%-67.1M | -246.27%-38.95M | 438.95%18.89M | 90.82%-2.84M | -890.39%-44.2M |
| End cash Position | -3.12%25.18M | -3.12%25.18M | -28.24%46.6M | -31.67%31.46M | -27.93%35.23M | -72.08%25.99M | -72.08%25.99M | -2.29%64.94M | -36.08%46.04M | -52.54%48.89M |
| Free cash flow | 64.49%-68.96M | 51.32%-24.56M | 92.27%-3.99M | 79.97%-10.67M | 23.41%-29.74M | 29.28%-194.2M | 11.36%-50.45M | 20.80%-51.63M | 18.49%-53.3M | 55.44%-38.83M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.